

IN THE CLAIMS:

1-6. (Canceled)

7. (New) A method for treating an allergic disease of type I comprising externally administering an effective amount of 3'-hydroxymethyl-4-hydroxypyrrolido[1,2-f]2',5'-piperazinedione.

8. (New) The method of claim 7, wherein the allergic disease is atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, pollinosis or allergic asthma.

9. (New) The method of claim 8, wherein the allergic disease is atopic dermatitis.

10. (New) The method of claim 7, wherein 3'-hydroxymethyl-4-hydroxypyrrolido[1,2-f]2',5'-piperazinedione is formulated in an external preparation comprising ointment, liquid, lotion, spray, inhalant, nasal drops, eye drops, and bath salts.

11. (New) The method of claim 7, wherein 3'-hydroxymethyl-4-hydroxypyrrolido[1,2-f]2',5'-piperazinedione is administered in a dose of from 1 mg/kg to 100 mg/kg.

12. (New) The method of claim 11, wherein 3'-hydroxymethyl-4-hydroxypyrrolido[1,2-f]2',5'-piperazinedione is administered in a dose of from 2.5 mg/kg to 50 mg/kg.